Αρχική World News Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours

Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours

Early results from a phase I study showed promising safety, tolerability, and efficacy following sequential intratumoural (IT) administration of MEDI1191, an IL-12 mRNA agent, followed by durvalumab (anti-PD-L1) in patients with advanced solid tumours who progressed on one or more lines of standard systemic treatment. These findings were reported at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on 1-2 March.

Dr. Omid Hamid, head of Translational Research and ImmunoOncology at The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate in Los Angeles, USA explained that IL-12 is a strong driver of the TH1 immune response. Systemically delivered recombinant IL-12 is poorly tolerated.  

MEDI1191 is a lipid nanoparticle-formulated therapy that was developed to be administered by IT injection in order to drive local IL-12 production and induce anti-tumour activity.

Data from preclinical models showed that IT IL-12 mRNA induced a potent TH1-mediated anti-tumour response, which could be further enhanced by PD-L1 blockade.

Dr. Hamid and co-investigators evaluated the safety and efficacy of MEDI1191 (IL-12 mRNA) in a phase I, multicentre, open-label, dose-escalation and expansion study (NCT03946800).

The dose escalation part 1 of this study aimed to determine the dose of MEDI1191 in combination with durvalumab at 1500 mg intravenously that was delivered every 4 weeks either sequentially or concurrently in patients with advanced solid tumours that included both superficial and deep-seated lesions. The study included patients who were immunotherapy-naïve or pre-treated, including anti-PD-1(L) and CTLA-4 pretreated solid tumours.

The primary endpoints for part 1 included safety and the determination of the maximum tolerated dose (MTD) as well as a pharmacodynamic active dose, and the secondary endpoints were efficacy according to the disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), pharmacokinetics, and immunogenicity. The study also includes an expansion part 2.

From May 2019 to December 2020, the study enrolled 10 patients with superficial lesions who were relegated to one of three dose escalation cohorts. Of these, 6 patients had received prior immunotherapy.

Preliminary analysis indicates MEDI1191 is safe

Regarding the co-primary endpoint of safety, no dose limiting toxicities, adverse events of special interest, treatment related adverse events ≥ Grade 3, or treatment-related serious adverse events were reported.

In the efficacy analysis, two partial responses (PRs) were demonstrated in patients that had received prior immunotherapy and also had PD-L1 negative tumours. Of these PRs, one occurred in a patient with mucosal melanoma who displayed tumour shrinkage of both injected and non-injected lesions following 2 doses of MEDI1191 that occurred prior to administration of sequential durvalumab. This patient was PD-1 and CTLA-4 pretreated with progression on those regimens. Another patient with PD-1 pretreated HNSCC showed response to therapy.

Preliminary findings from the pharmacodynamic analysis indicated that MEDI1191 induced transient elevation of serum levels of IL-12, as well as concordant changes in IFN-gamma and CXCL10.

Conclusions

Based on these data the authors concluded that the IT MEDI1191 sequentially delivered with durvalumab was well-tolerated and showed encouraging efficacy.

The treatment also demonstrated preliminary anti-tumour and pharmacodynamic activity in immunotherapy pre-treated patients that was consistent with the expected mechanism of action. However, they advised that these preliminary data require further validation.

They noted that this study is active and recruiting. Current regimes will evaluate concurrent administration of MEDI1191 and durvalamab in cutaneous/subcutaneous lesions and in virsceral metastases.

This study was funded by AstraZeneca.

Reference

19O – Hamid O, Hellman M, Carneiro B, et al. Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions. ESMO Targeted Anticancer Therapies (TAT) Virtual Congress (1-2 March 2021).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...